FY2025 EPS Estimates for Alkermes Decreased by Analyst

Alkermes plc (NASDAQ:ALKS) – Leerink Partnrs cut their FY2025 earnings estimates for shares of Alkermes in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $1.50 per share for the year, down from their previous forecast of $1.55. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. Leerink Partnrs also issued estimates for Alkermes’ FY2026 earnings at $1.84 EPS.

ALKS has been the topic of a number of other research reports. HC Wainwright reiterated a “neutral” rating and set a $37.00 price target on shares of Alkermes in a research report on Friday, October 25th. Cantor Fitzgerald cut their price target on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price objective (down from $38.00) on shares of Alkermes in a report on Friday, October 25th. Mizuho boosted their target price on shares of Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, The Goldman Sachs Group decreased their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Alkermes Trading Down 1.2 %

ALKS stock opened at $31.53 on Thursday. Alkermes has a 52-week low of $22.90 and a 52-week high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The firm has a market cap of $5.10 billion, a P/E ratio of 16.17, a PEG ratio of 1.68 and a beta of 0.49. The company’s 50-day simple moving average is $29.82 and its 200-day simple moving average is $28.27.

Institutional Investors Weigh In On Alkermes

A number of institutional investors have recently made changes to their positions in ALKS. Bank of Montreal Can increased its holdings in Alkermes by 111.4% in the 2nd quarter. Bank of Montreal Can now owns 47,756 shares of the company’s stock valued at $1,158,000 after purchasing an additional 25,162 shares during the last quarter. Algert Global LLC purchased a new position in shares of Alkermes during the second quarter worth $390,000. Creative Planning grew its stake in shares of Alkermes by 28.0% in the second quarter. Creative Planning now owns 33,365 shares of the company’s stock valued at $804,000 after buying an additional 7,296 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Alkermes by 10.7% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 244,857 shares of the company’s stock valued at $5,901,000 after buying an additional 23,600 shares during the period. Finally, Dana Investment Advisors Inc. lifted its stake in Alkermes by 47.0% during the 2nd quarter. Dana Investment Advisors Inc. now owns 27,968 shares of the company’s stock worth $674,000 after acquiring an additional 8,940 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Alkermes

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares of the company’s stock, valued at $732,964.05. This trade represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Craig C. Hopkinson sold 58,996 shares of Alkermes stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.08, for a total value of $1,774,599.68. Following the completion of the sale, the executive vice president now owns 83,300 shares in the company, valued at $2,505,664. This represents a 41.46 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 248,656 shares of company stock valued at $7,807,326. 4.89% of the stock is owned by company insiders.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.